Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating Zelenectide Pevedotin (formerly BT8009), a Bicycle® Drug Conjugate (BDC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts, USA. For more information, visit bicycletherapeutics.com
Culture is key and all Bicycle employees actively embrace and role model our company values:
Hybrid: At Bicycle, we benefit from a hybrid style working arrangement, allowing our employees where possible the opportunity to collaborate and engage with their coworkers in person while also benefiting from the flexibility of home remote working. A typical hybrid arrangement for this role is 3 days onsite per week at our Cambridge, UK office, with the option of the remainder of your working week being remote.
As Enterprise Architect, you will help enable Bicycle Therapeutics’ success by shaping and delivering the technology backbone that supports our growth, pipeline and operations across Development, Supply and G&A. You will connect existing and future systems, platforms and data capabilities so teams can work effectively, make better decisions and scale with confidence, including in regulated settings where compliance, quality and data integrity matter.
This is a strategic design and delivery-focused role. You will make practical, secure and scalable technology choices, reusing and evolving existing solutions where they fit and replacing them where business needs have moved on. You will also be accountable for turning architecture direction into delivered capability, strengthening trusted data flow, data warehouse or lakehouse capabilities, analytics and AI-ready data products so data directly enables business processes, operational visibility and decision-making.
In this key technology leadership role for IT at Bicycle, reporting to the VP, IT & Cybersecurity, you will lead the technical architecture team across cloud/solution architecture, AI Ops and network/infrastructure engineering, partnering widely across Bicycle to turn architecture strategy into delivered solutions.
As a fluent communicator you will also be able to explain complex technical choices simply so leaders and teams can make confident decisions and deliver meaningful change.
Bicycle Therapeutics is committed to building a diverse workforce that is representative of the communities we serve. We recognize that diverse and inclusive teams build a stronger and more innovative company. Therefore, all qualified applicants will be considered for employment, and we do not discriminate on the basis of race, religion, colour, gender, sexual orientation, age, disability status, marital status, or veteran status.
Bicycle Therapeutics is committed to building a diverse workforce that is representative of the communities we serve. We recognize that diverse and inclusive teams build a stronger and more innovative company. Therefore, all qualified applicants will be considered for employment, and we do not discriminate on the basis of race, religion, colour, gender, sexual orientation, age, disability status, marital status, or veteran status.
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.
